MX393493B - Tratamiento o prevención de eventos cardiovasculares. - Google Patents

Tratamiento o prevención de eventos cardiovasculares.

Info

Publication number
MX393493B
MX393493B MX2020009511A MX2020009511A MX393493B MX 393493 B MX393493 B MX 393493B MX 2020009511 A MX2020009511 A MX 2020009511A MX 2020009511 A MX2020009511 A MX 2020009511A MX 393493 B MX393493 B MX 393493B
Authority
MX
Mexico
Prior art keywords
sub
sup
alkyl
optionally substituted
independently represent
Prior art date
Application number
MX2020009511A
Other languages
English (en)
Other versions
MX2020009511A (es
Inventor
Mark Nidorf
Original Assignee
Murray & Poole Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50626218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX393493(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2012904828A external-priority patent/AU2012904828A0/en
Application filed by Murray & Poole Entpr Ltd filed Critical Murray & Poole Entpr Ltd
Publication of MX2020009511A publication Critical patent/MX2020009511A/es
Publication of MX393493B publication Critical patent/MX393493B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

Un método de tratamiento o prevención de un evento cardiovascular en un sujeto con enfermedad vascular ateroesclerótica que comprende los pasos de: b) administrar una cantidad terapéuticamente efectiva de un compuesto de la fórmula (I), un derivado de colchicina conocido y/o una sal del mismo Fórmula (I) (ver Fórmula) en la cual: R1, R2, R3, R4, R9, R10, R11 y R12 representan independientemente hidrógeno, C1-4 alquilo, C2-4 alquenilo, C3-6 cicloalquilo, halógeno, C1-4 haloalquilo, nitro, amino, C2-4 acilamino, C1-4 alquilo o dialquilamino, hidroxilo, C1-4 alcoxi, C1-4 alquiltio, un grupo de la fórmula - SO2N(Rx)2 o SO2Rx donde Rx es C1-4 alquilo, C1-4 aciloxi, o fenilo opcionalmente sustituido, fenoxi opcionalmente sustituido; R7 y R8 representan independientemente hidrógeno, C1-4 alquilo o C1-4 acilo; y R5', R5", R6' y R6" representan independientemente hidrógeno, C1-4 alquilo, C2-4 alquenilo, C3-6 cicloalquilo, halógeno, C1-4 haloalquilo, nitro, amino, C2-4 acilamino, hidroxilo, C1-4 alcoxi o C1-4 alquiltio un grupo de la fórmula -SO2N(Rx)2 o SO2Rx donde Rx es C1-4 alquilo, C1-4 aciloxi, o fenilo opcionalmente sustituido.
MX2020009511A 2012-11-02 2013-11-01 Tratamiento o prevención de eventos cardiovasculares. MX393493B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904828A AU2012904828A0 (en) 2012-11-02 Treatment and Prevention of Coronary Thrombosis
AU2012904868A AU2012904868A0 (en) 2012-11-05 Treatment or Prevention of Cardiovascular Events
PCT/AU2013/001261 WO2014066944A1 (en) 2012-11-02 2013-11-01 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative

Publications (2)

Publication Number Publication Date
MX2020009511A MX2020009511A (es) 2022-05-09
MX393493B true MX393493B (es) 2025-03-21

Family

ID=50626218

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005637A MX375082B (es) 2012-11-02 2013-11-01 Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina.
MX2020009511A MX393493B (es) 2012-11-02 2013-11-01 Tratamiento o prevención de eventos cardiovasculares.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015005637A MX375082B (es) 2012-11-02 2013-11-01 Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina.

Country Status (24)

Country Link
US (18) US10265281B2 (es)
EP (2) EP3964205A1 (es)
JP (1) JP6356684B2 (es)
KR (7) KR102858016B1 (es)
CN (2) CN108721265B (es)
AU (4) AU2013337605B2 (es)
BR (1) BR112015010063B1 (es)
CA (1) CA2894417C (es)
CL (1) CL2015001154A1 (es)
DK (1) DK2914255T3 (es)
EA (1) EA032515B1 (es)
ES (1) ES2900740T3 (es)
HR (1) HRP20211644T1 (es)
HU (1) HUE056810T2 (es)
IL (1) IL238519B (es)
LT (1) LT2914255T (es)
MX (2) MX375082B (es)
MY (1) MY177898A (es)
NZ (2) NZ747657A (es)
PL (1) PL2914255T3 (es)
PT (1) PT2914255T (es)
SG (2) SG11201503440UA (es)
SI (1) SI2914255T1 (es)
WO (1) WO2014066944A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147994A1 (en) 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
JP6356684B2 (ja) 2012-11-02 2018-07-11 マレイ・アンド・プール・エンタープライゼズ・リミテッド コルヒチン誘導体の投与による心血管イベントの処置または予防
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
EP3283063A1 (en) * 2015-04-17 2018-02-21 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
US10226423B1 (en) 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
CA3089781A1 (en) 2018-02-02 2019-08-08 Murray & Poole Enterprises, Ltd Use of colchicine to inhibit tumor growth and metastases
AU2019295499B2 (en) 2018-06-29 2025-02-13 Alberta Health Services Methods and uses of colchicine derivatives
ES2983568T3 (es) 2018-09-24 2024-10-23 Amarin Pharmaceuticals Ie Ltd Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
KR102112456B1 (ko) 2019-11-13 2020-05-19 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
EP3821889A1 (en) * 2019-11-15 2021-05-19 Institut de Cardiologie de Montréal Methods for using low-dose colchicine after myocarial infarction
CA3099143A1 (en) 2019-11-15 2021-01-26 Institut De Cardiologie De Montreal Early administration of low-dose colchicine after myocardial infarction
WO2021092703A1 (en) 2019-11-15 2021-05-20 Institut De Cardiologie De Montreal Methods for using low-dose colchicine after myocardial infarction
KR102150821B1 (ko) 2020-01-22 2020-09-03 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR20210095249A (ko) 2020-01-22 2021-08-02 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR102177781B1 (ko) 2020-04-27 2020-11-12 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친, 우르소데옥시콜산 및 비페닐디메틸디카르복실레이트의 복합제제
US20240075045A1 (en) * 2020-12-15 2024-03-07 Romeg Therapeutics Llc Methods and compositions for treating pericarditis
WO2022212655A1 (en) * 2021-03-31 2022-10-06 Amarin Pharmaceuticals Ireland Limited Compositions comprising epa and colchicine and methods of using the same for reducing the risk of cardiovascular events in a subject
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN114656429A (zh) * 2021-11-18 2022-06-24 江苏新元素医药科技有限公司 一类抗炎镇痛化合物及其用途
WO2024224234A1 (en) * 2023-04-23 2024-10-31 Vishal Kumar Pharmaceutical composition in powder form in sachets and tablet of 90 mg ticagrelor + 20 mg rosuvastatin
CN118717741A (zh) * 2024-01-15 2024-10-01 华中科技大学同济医学院附属协和医院 秋水仙碱在制备用于增加冠状动脉斑块纤维帽厚度药物中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
JP2000034224A (ja) 1998-05-11 2000-02-02 Freunt Ind Co Ltd 徐放性錠剤、その添加剤組成物及びそれらの製造方法
US20020169145A1 (en) 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
CN1434713A (zh) 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
WO2002072033A2 (en) 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
AU2002344905A1 (en) 2001-12-21 2003-07-09 Prospective Concepts Ag Push rod for a pneumatic element
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006063091A2 (en) 2004-12-06 2006-06-15 Ronald Freudenberger Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity
US20060171948A1 (en) * 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
US20060286108A1 (en) 2005-06-16 2006-12-21 Bell Katherine A Topical compositions for the treatment of chronic wounds
CN1939290A (zh) * 2005-09-29 2007-04-04 陆宪光 秋水仙碱及它的衍生物的医学用途
WO2007048004A2 (en) * 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Compounds for enhancing hypoxia inducible factor activity and methods of use
US8697387B2 (en) 2006-06-02 2014-04-15 DiscoverRx Corporation Methods for identifying agents and their use for the prevention of restenosis
AP2416A (en) 2006-06-09 2012-06-01 Sanol Arznei Schwarz Gmbh Stabilized pharmaceutical compositions comprising fesoterodine.
WO2008131192A2 (en) * 2007-04-18 2008-10-30 The Trustees Of Columbia University In The City Of New York Crystalline cholestrol and prevention of atherosclerosis
US20090093548A1 (en) 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
CN101485638A (zh) 2008-01-18 2009-07-22 普尔药物科技开发（深圳）有限公司 秋水仙碱双层渗透泵控释片及其制备方法
CN101485637B (zh) 2008-01-18 2011-03-30 普尔药物科技开发（深圳）有限公司 秋水仙碱骨架控释片或胶囊
WO2009097450A1 (en) 2008-01-30 2009-08-06 Dexcom. Inc. Continuous cardiac marker sensor system
CN101536990A (zh) 2008-03-18 2009-09-23 普尔药物科技开发（深圳）有限公司 秋水仙碱胃漂浮缓释片及其制备方法
EP2262786A4 (en) 2008-04-15 2014-07-09 Takeda Pharmaceuticals Usa Inc COLCHICIN SOLIDS FORMAT, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
DE602008004113D1 (de) 2008-05-28 2011-02-03 Indena Spa Verfahren zur Glycosidierung von Colchicin und Thiocolchicin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
CN101732274A (zh) 2008-11-19 2010-06-16 普尔药物科技开发（深圳）有限公司 秋水仙碱双层缓释片及其制备方法
US7820681B1 (en) * 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
EP2405898A2 (en) 2009-03-09 2012-01-18 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
EP2435403A4 (en) 2009-05-27 2015-04-01 Takeda Pharmaceuticals Usa Inc THIOCOLCHICINE DERIVATIVES AND MANUFACTURING AND USE METHOD THEREFOR
US20110046228A1 (en) 2009-08-20 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for administration of colchicine with grapefruit juice
US20110046227A1 (en) * 2009-08-21 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
DK2470499T3 (da) 2009-08-26 2019-09-23 Alberta Health Services Nye colchicin-derivativer, fremgangsmåder og anvendelse deraf
CN105193761B (zh) 2009-11-13 2019-12-06 阿斯利康(瑞典)有限公司 双层片剂
US20110178180A1 (en) 2010-01-18 2011-07-21 Kurt Nielsen Deuterium-enriched colchicine, thiocolchicine, and derivatives thereof; methods of preparation; and use thereof
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EA028495B1 (ru) 2012-04-13 2017-11-30 Саймабэй Терапьютикс, Инк. Пероральная композиция для лечения подагры на основе (-)-галофената и колхицина
JP6356684B2 (ja) 2012-11-02 2018-07-11 マレイ・アンド・プール・エンタープライゼズ・リミテッド コルヒチン誘導体の投与による心血管イベントの処置または予防
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina

Also Published As

Publication number Publication date
KR20250138815A (ko) 2025-09-22
MX2020009511A (es) 2022-05-09
KR102666548B1 (ko) 2024-05-21
AU2019232879B2 (en) 2021-09-09
DK2914255T3 (da) 2021-10-25
AU2024205084A1 (en) 2024-08-15
US20250302776A1 (en) 2025-10-02
CA2894417A1 (en) 2014-05-08
US11944594B2 (en) 2024-04-02
KR20250154562A (ko) 2025-10-28
EP3964205A1 (en) 2022-03-09
US20250381156A1 (en) 2025-12-18
AU2018203715A1 (en) 2018-06-21
US20250082590A1 (en) 2025-03-13
US20210069131A1 (en) 2021-03-11
US20230414539A1 (en) 2023-12-28
US20190374487A1 (en) 2019-12-12
KR20240074883A (ko) 2024-05-28
BR112015010063B1 (pt) 2021-11-09
KR20220001518A (ko) 2022-01-05
US12280025B2 (en) 2025-04-22
SG11201503440UA (en) 2015-06-29
KR102858016B1 (ko) 2025-09-11
KR20150102969A (ko) 2015-09-09
KR20210020170A (ko) 2021-02-23
EA032515B1 (ru) 2019-06-28
US10206891B2 (en) 2019-02-19
AU2013337605B2 (en) 2018-03-01
US20150272912A1 (en) 2015-10-01
CN108721265B (zh) 2022-12-02
US20230270698A1 (en) 2023-08-31
US11026899B2 (en) 2021-06-08
US11026901B2 (en) 2021-06-08
US20210069133A1 (en) 2021-03-11
HRP20211644T1 (hr) 2022-02-04
US20170326083A1 (en) 2017-11-16
US11026900B2 (en) 2021-06-08
IL238519A0 (en) 2015-06-30
EP2914255A1 (en) 2015-09-09
BR112015010063A2 (pt) 2018-12-18
EA201500484A1 (ru) 2015-10-30
HUE056810T2 (hu) 2022-03-28
US11666545B2 (en) 2023-06-06
AU2018203715B2 (en) 2019-06-20
PL2914255T3 (pl) 2022-01-03
AU2013337605A1 (en) 2015-05-21
US20240082179A1 (en) 2024-03-14
NZ707640A (en) 2019-03-29
JP2015535264A (ja) 2015-12-10
NZ747657A (en) 2019-12-20
US10842761B2 (en) 2020-11-24
SG10201703586PA (en) 2017-06-29
AU2019232879A1 (en) 2019-10-10
US20150196513A1 (en) 2015-07-16
SI2914255T1 (sl) 2021-12-31
CN108721265A (zh) 2018-11-02
MX2015005637A (es) 2016-02-03
CN104918613B (zh) 2018-05-25
US20150196514A1 (en) 2015-07-16
CN104918613A (zh) 2015-09-16
EP2914255A4 (en) 2016-06-29
US9744144B2 (en) 2017-08-29
US20210069132A1 (en) 2021-03-11
US11944595B2 (en) 2024-04-02
LT2914255T (lt) 2021-11-10
WO2014066944A1 (en) 2014-05-08
AU2021282491B2 (en) 2024-05-09
US10842762B2 (en) 2020-11-24
US20230270697A1 (en) 2023-08-31
IL238519B (en) 2020-04-30
ES2900740T3 (es) 2022-03-18
CL2015001154A1 (es) 2015-12-18
US12364675B2 (en) 2025-07-22
MX375082B (es) 2025-03-06
EP2914255B1 (en) 2021-07-21
JP6356684B2 (ja) 2018-07-11
US20210077432A1 (en) 2021-03-18
PT2914255T (pt) 2021-10-27
CA2894417C (en) 2019-09-10
MY177898A (en) 2020-09-24
US20190117598A1 (en) 2019-04-25
AU2021282491A1 (en) 2022-01-06
US10265281B2 (en) 2019-04-23
US20190314303A1 (en) 2019-10-17
US12233035B2 (en) 2025-02-25
KR20230049751A (ko) 2023-04-13

Similar Documents

Publication Publication Date Title
MX2020009511A (es) Tratamiento o prevención de eventos cardiovasculares.
EA201290919A1 (ru) Индазольные соединения и их применение
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
ATE533489T1 (de) Behandlung von multiplem myelom
HRP20110451T1 (hr) Upotreba izotiocijanata kao sredstva protiv mieloma
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
EA200802213A1 (ru) Способы лечения заболеваний крови
RU2013144215A (ru) Средство для борьбы с эндопаразитами
EP2629799A4 (en) TOPICAL BASE AND ACTIVE COMPOSITIONS AND PROCESS FOR THE CARE AND TREATMENT OF THE SKIN
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
EA201070250A1 (ru) Противомикробный парентеральный состав
BR112013028786A2 (pt) método e composição de tratamento de sementes
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
WO2011098408A3 (de) Hydrazin-substituierte anthranilsäurederivate
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
BR112015022571A2 (pt) método de tratamento de esteatose hepática
DE602007010818D1 (de) Verfahren zur behandlung disruptiver verhaltensstörungen
SE0301885D0 (sv) New use IV
EA201291384A1 (ru) Терапевтические агенты 976